SCHEMBL6010066

SCHEMBL6010066

CCC(NC(=S)NC1CCCCC1)N1CCN(C)CC1

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.50
NPC1 O15118 1/20 0.48
ALPL P05186 1/20 0.47
ALPI P09923 1/20 0.47
ALPG P10696 1/20 0.47
KDM4E B2RXH2 1/20 0.47
HTT P42858 3/20 0.44
ALDH1A1 P00352 2/20 0.44
TP53 P04637 1/20 0.44
CYP3A4 P08684 1/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
SIGMAR1 Q99720 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6010329 0.84 KMT2A (0.56) KMT2ANPC1ALPLALPIALPG
SCHEMBL491867 0.72 EPHX1 (0.62) NPC1KDM4EALDH1A1CYP3A4SMN1; SMN2
SCHEMBL11503858 0.70 ALDH1A1 (0.67) KMT2ANPC1ALPLALPIALPG
SCHEMBL15007416 0.70 NPC1 (0.52) KMT2ANPC1ALPLALPIALPG
SCHEMBL10720550 0.69 SIGMAR1 (0.43) KDM4EHTTSMN1; SMN2SIGMAR1
SCHEMBL6010068 0.69 KMT2A (0.59) KMT2ANPC1HTTALDH1A1TP53
SCHEMBL843570 0.67 KMT2A (0.61) KMT2AKDM4EHTTALDH1A1TP53
SCHEMBL8939922 0.66 KDM4E (0.45) KMT2ANPC1KDM4EALDH1A1SIGMAR1
SCHEMBL10724047 0.66 SIGMAR1 (0.45) KDM4EALDH1A1SIGMAR1
SCHEMBL491492 0.66 ALDH1A1 (1.00) NPC1KDM4EHTTALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7022721-B1 Method and composition for rejuvenating cells, tissues, organs, hair and nails ULRICH PETER C 2006-04-04 US disclosed
EP-1368029-A4 METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS FARRINGTON PHARMACEUTICALS LLC (US) 2006-02-15 EP disclosed
US-20050245512-A1 Method and composition for rejuvinating cells, tissues organs, hair and nails ULRICH PETER C 2005-11-03 US disclosed
US-6777557-B2 Method and composition for rejuvenating cells, tissues organs, hair and nails FARRINGTON PHARMACEUTICALS, LLC 2004-08-17 US disclosed
EP-1368029-A2 METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS Farrington Pharmaceuticals, LLC (US) 2003-12-10 EP disclosed
US-20020188015-A1 Method and composition for rejuvinating cells, tissues organs, hair and nails FARRINGTON PHARMACEUTICALS, LLC 2002-12-12 US disclosed
WO-2002062301-A2 METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS FARRINGTON PHARMACEUTICALS, LLC (US) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020188015-A1 Method and composition for rejuvinating cells, tissues organs, hair and nails TERT, TELO2, HKDC1 KMT2A 1145/4885NPC1 3338/4885ALPL 977/4885
US-20050245512-A1 Method and composition for rejuvinating cells, tissues organs, hair and nails TERT, TELO2, HKDC1 KMT2A 1145/4885NPC1 3338/4885ALPL 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.